Ignite Creation Date:
2025-12-24 @ 5:53 PM
Ignite Modification Date:
2026-03-18 @ 3:43 AM
Study NCT ID:
NCT02674568
Status:
COMPLETED
Last Update Posted:
2021-07-30
First Post:
2016-01-29
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer
Sponsor:
AbbVie
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-01-25
Start Date Type:
ACTUAL
Primary Completion Date:
2018-10-19
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-10-19
Completion Date Type:
ACTUAL
First Submit Date:
2016-01-29
First Submit QC Date:
None
Study First Post Date:
2016-02-04
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2019-09-30
Results First Submit QC Date:
None
Results First Post Date:
2019-10-23
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-07-28
Last Update Post Date:
2021-07-30
Last Update Post Date Type:
ACTUAL